COVA322

Home
Ligands
COVA322

GtoPdb Ligand ID: 10469

Comment: COVA322 is a bispecific TNF/IL-17A inhibitor that was designed by Covagen for the treatment of inflammatory diseases including psoriasis, psoriatic arthritis, and rheumatoid arthritis [2]. Structurally COVA322 is a fusion protein containing an antibody that binds to TNF (in this case the light chain of adalimumab) and a Fyn SH3-derived protein (Fynomer) that binds to IL-17A [1]. The fusion protein was produced in transiently transfected Chinese hamster ovary (CHO) cells. COVA322 was able to simultaneously bind TNF and IL-17A.
Clinical development of COVA322 was discontinued due to an unacceptable safety profile that was detected in Phase 1 trial.

Immunopharmacology Comments
COVA322 was advanced to Phase 1 clinical evaluation in patients with stable chronic moderate-to-severe plaque psoriasis. Unfortunately the study (NCT02243787) was terminated when it became evident that COVA322's safety profile was unacceptable.

Immunopharmacology Comments

COVA322 was advanced to Phase 1 clinical evaluation in patients with stable chronic moderate-to-severe plaque psoriasis. Unfortunately the study (NCT02243787) was terminated when it became evident that COVA322's safety profile was unacceptable.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Psoriasis	Disease Ontology: DOID:8893	Failed Phase 1 clinical lead for plaque psoriasis. Concerns about COVA322's safety profile led to development being discontinued.